Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.

Background: In type 2 diabetes mellitus, fasting blood glucose values are increased due to increased glycogenolysis and gluconeogenesis. As miglitol (BAY m-1099), an absorbable alpha-glucosidase inhibitor, can inhibit glycogenolysis, we investigated whether 200 mg miglitol ingested at bedtime could decrease fasting blood glucose values.

Methods: Twelve type 2 diabetic patients participated in a double-blind, randomised, placebo-controlled, cross-over study.

Worldwide clinical data on efficacy and safety of ciprofloxacin.

During the clinical trials 8,861 patients have been treated with ciprofloxacin worldwide. 3,822 of the therapeutic courses were valid for analysis of efficacy according to FDA standards. The following dosages were usually administered: UTI: 100 to 500 mg twice daily orally or 100 mg twice daily intravenously; RTI: 250 to 1000 mg twice daily orally or 200 mg twice daily intravenously; septicemia: 200 mg intravenously twice daily; gonorrhea: 250 to 500 mg single tablet orally; all other infections: 500 to 1000 mg twice daily orally or 200 mg twice daily intravenously.

Long-term oral ciprofloxacin for infection prophylaxis in allogeneic bone marrow transplantation.

The efficacy of oral ciprofloxacin to prevent bacterial infections during the first three months after allogeneic bone marrow transplantation (BMT) was assessed prospectively. Twenty-three recipients of lymphocyte depleted marrow grafts received ciprofloxacin orally, 500 mg twice daily for 90 days after BMT. Nine patients had no infections during ciprofloxacin prophylaxis; in the remaining 14 patients 19 febrile episodes occurred.

Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration.

Penetration activities of ciprofloxacin into female genital tract tissues were studied following a single oral administration of 500 mg and an intravenous injection of 100 mg. Serum and tissue concentrations were within the same order of magnitude 1 and 3 h after oral administration; 3 h after intake of ciprofloxacin, however, tissue concentrations exceeded the corresponding serum levels twofold. Similarly, tissue concentrations following intravenous injection exceeded the corresponding serum levels by 60-190% 0.

Efficacy and tolerability of single-dose versus six-day treatment of candidal vulvovaginitis with vaginal tablets of clotrimazole.

One hundred ninety-nine female patients with candidal vulvovaginitis were included in an open, randomized, mycologically controlled study carried out at three Dutch gynecologic clinics to determine the efficacy and tolerability of a single vaginal tablet containing 500 mg clotrimazole in comparison with a 6-day treatment with vaginal tablets containing 100 mg clotrimazole. Both groups were comparable in age, body weight, and duration and severity of the infection, and in both groups the percentage of patients who were also treated for vulvitis with a 1% clotrimazole cream and the percentage of the male partners who were treated were equal. Four weeks after therapy, 84 of the 102 patients (82.

Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

In an open study 28 patients were treated for complicated UTI with ciprofloxacin 250 mg every 12 h for 10 days. The most frequently isolated species were Escherichia coli and Klebsiella pneumoniae. All pathogens were sensitive to ciprofloxacin in vitro.

One-dose therapy of Candida vaginitis. I. Results of an open multicentre trial.

90 female patients suffering from Candida vaginitis were included in an open, mycologically controlled study, carried out at three gynaecological clinics, to investigate the efficacy and tolerance of one single vaginal tablet containing 500 mg clotrimazole (Canesten 1). In 40% of the patients the infection was considered to be mild and in 60% severe. In order to confirm the diagnosis and to evaluate the therapeutic effect (before application and 1 as well as 4 weeks after therapy), the following criteria were considered: (1) identification of Candida species on direct microscopic examination (wet film) and also by culture on a Nickerson medium, and (2) influence on the clinical symptoms, such as itching, burning, pathological changes of the vaginal mucosa, thrush.